MX341482B - Antagonistas del receptor ep4 y su uso en el tratamiento de enfermedades mediadas por la il-23. - Google Patents
Antagonistas del receptor ep4 y su uso en el tratamiento de enfermedades mediadas por la il-23.Info
- Publication number
- MX341482B MX341482B MX2012009503A MX2012009503A MX341482B MX 341482 B MX341482 B MX 341482B MX 2012009503 A MX2012009503 A MX 2012009503A MX 2012009503 A MX2012009503 A MX 2012009503A MX 341482 B MX341482 B MX 341482B
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- allergy
- compound
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- 101150109738 Ptger4 gene Proteins 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 4
- 208000026935 allergic disease Diseases 0.000 abstract 4
- 230000007815 allergy Effects 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000026278 immune system disease Diseases 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 4
- 230000003042 antagnostic effect Effects 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28250610P | 2010-02-22 | 2010-02-22 | |
| PCT/JP2011/000994 WO2011102149A1 (en) | 2010-02-22 | 2011-02-22 | Use of ep4 receptor antagonists in the treatment of il-23 mediated diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2012009503A MX2012009503A (es) | 2012-09-12 |
| MX341482B true MX341482B (es) | 2016-08-22 |
Family
ID=44482754
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012009503A MX341482B (es) | 2010-02-22 | 2011-02-22 | Antagonistas del receptor ep4 y su uso en el tratamiento de enfermedades mediadas por la il-23. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9457084B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2538978B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6152643B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101780666B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN102770159A (cg-RX-API-DMAC7.html) |
| BR (1) | BR112012020236A2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA2789665C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2600355T3 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1249401A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX341482B (cg-RX-API-DMAC7.html) |
| RU (1) | RU2571816C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2011102149A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3296B1 (ar) | 2012-06-29 | 2018-09-16 | Lilly Co Eli | مركبات فينوكسي إيثيل بيبريدين |
| UA115576C2 (uk) * | 2012-12-06 | 2017-11-27 | Байєр Фарма Акцієнгезелльшафт | Похідні бензимідазолу як антагоністи ер4 |
| EP2765128A1 (en) * | 2013-02-07 | 2014-08-13 | Almirall, S.A. | Substituted benzamides with activity towards EP4 receptors |
| TW201443004A (zh) | 2013-02-15 | 2014-11-16 | Lilly Co Eli | 苯氧基乙氧基化合物 |
| TWI636046B (zh) | 2013-05-17 | 2018-09-21 | 美國禮來大藥廠 | 苯氧基乙基二氫－１ｈ－異喹啉化合物 |
| SI3083562T1 (sl) | 2013-12-17 | 2017-11-30 | Eli Lilly And Company | Derivati fenoksietil cikličnih aminov in njihova aktivnost kot modulatorji EP4 receptorja |
| TW201607943A (zh) * | 2013-12-19 | 2016-03-01 | 拜耳製藥公司 | 作為ｅｐ４配體之新穎苯并咪唑衍生物 |
| MX376175B (es) | 2014-03-06 | 2025-03-07 | Aratana Therapeutics Inc | Composiciones de grapiprant y metodos para usar las mismas. |
| US12109218B2 (en) | 2014-12-09 | 2024-10-08 | Aratana Therapeutics, Inc. | Compositions of grapiprant and methods for using the same |
| CN108473497B (zh) * | 2015-10-16 | 2021-09-10 | 卫材R&D 管理有限公司 | Ep4拮抗剂 |
| US10342785B2 (en) * | 2016-11-04 | 2019-07-09 | Askat Inc. | Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer |
| MA55695A (fr) | 2017-01-23 | 2022-02-23 | Genentech Inc | Composés chimiques comme inhibiteurs de l'activité interleukine-1 |
| CN109836434B (zh) * | 2017-11-27 | 2020-09-25 | 上海宇耀生物科技有限公司 | 噻吩并环类化合物及其合成方法和应用 |
| CN112292128A (zh) | 2018-04-16 | 2021-01-29 | 阿瑞斯医疗有限公司 | Ep4抑制剂和其用途 |
| US10239885B1 (en) | 2018-06-18 | 2019-03-26 | Avista Pharma Solutions, Inc. | Compound 1-[2-[4-(2-ethyl-6,8-dimethylimidazo[1,2-α]pyrazin-3-yl)phenyl]ethyl]-3-(p-tolylsulfonyl)urea as a prostaglandin EP4 receptor antagonist |
| US20210315909A1 (en) | 2018-07-11 | 2021-10-14 | Arrys Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| WO2020018970A1 (en) | 2018-07-20 | 2020-01-23 | Genentech, Inc. | Sulfonylurea compounds as inhibitors of interleukin-1 activity |
| MX2021000780A (es) | 2018-07-20 | 2021-03-31 | Hoffmann La Roche | Compuestos de sulfonimidamida como inhibidores de la actividad de interleucina-1. |
| HUE066335T2 (hu) | 2018-10-05 | 2024-07-28 | Annapurna Bio Inc | Vegyületek és készítmények APJ receptor aktivitáshoz kapcsolódó állapotok kezelésére |
| WO2020160075A1 (en) | 2019-01-30 | 2020-08-06 | Avista Pharma Solutions, Inc. | Chemical compounds |
| MX2021009251A (es) | 2019-01-30 | 2021-09-21 | Avista Pharma Solutions Inc | Proceso de sintesis y nuevos compuestos intermedios. |
| CN115697317A (zh) * | 2020-04-08 | 2023-02-03 | 株式会社AskAt | Ep4受体拮抗剂用于治疗肝癌、黑色素瘤、淋巴瘤和白血病的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HN2001000224A (es) | 2000-10-19 | 2002-06-13 | Pfizer | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos. |
| IL164263A0 (en) | 2002-04-12 | 2005-12-18 | Pfizer | Use of ep4 receptor ligands on the treatment of il-6 involved diseases |
| GB0302094D0 (en) | 2003-01-29 | 2003-02-26 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| DE602004013938D1 (de) * | 2003-01-29 | 2008-07-03 | Asterand Uk Ltd | Hemmstoffe des ep4-rezeptors |
| AU2004268839A1 (en) | 2003-09-03 | 2005-03-10 | Pfizer Inc. | Phenyl or pyridyl amide compounds as prostaglandin E2 antagonists |
| CN1946391A (zh) * | 2004-04-20 | 2007-04-11 | 辉瑞产品公司 | 包含α－2－δ配体的组合 |
| KR20070006891A (ko) | 2004-05-04 | 2007-01-11 | 화이자 인코포레이티드 | 치환된 메틸 아릴 또는 헤테로아릴 아미드 화합물 |
| ES2344310T3 (es) * | 2005-03-11 | 2010-08-24 | Raqualia Pharma Inc | Formas cristalinas de un derivado de imidazol. |
| EP1886987A1 (en) * | 2006-08-11 | 2008-02-13 | Givaudan S.A. | Process for producing 2,2,3-trimethylcyclopent-3-enecarbaldehyde (campholytic aldehyde) |
| JP5259592B2 (ja) * | 2006-08-11 | 2013-08-07 | メルク カナダ インコーポレイテッド | Ｅｐ４受容体リガンドとしてのチオフェンカルボキサミド誘導体 |
-
2011
- 2011-02-22 CA CA2789665A patent/CA2789665C/en active Active
- 2011-02-22 CA CA3009937A patent/CA3009937C/en active Active
- 2011-02-22 MX MX2012009503A patent/MX341482B/es active IP Right Grant
- 2011-02-22 EP EP11744440.6A patent/EP2538978B1/en active Active
- 2011-02-22 CN CN2011800104626A patent/CN102770159A/zh active Pending
- 2011-02-22 US US13/580,323 patent/US9457084B2/en active Active
- 2011-02-22 ES ES11744440.6T patent/ES2600355T3/es active Active
- 2011-02-22 KR KR1020127024115A patent/KR101780666B1/ko active Active
- 2011-02-22 RU RU2012140450/15A patent/RU2571816C2/ru active
- 2011-02-22 BR BR112012020236A patent/BR112012020236A2/pt not_active Application Discontinuation
- 2011-02-22 WO PCT/JP2011/000994 patent/WO2011102149A1/en not_active Ceased
- 2011-02-22 CN CN201711045618.XA patent/CN107693518A/zh active Pending
- 2011-02-22 JP JP2012538520A patent/JP6152643B2/ja active Active
-
2017
- 2017-01-27 JP JP2017013578A patent/JP2017095511A/ja not_active Withdrawn
-
2018
- 2018-06-15 HK HK18107808.7A patent/HK1249401A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2538978A4 (en) | 2013-10-16 |
| HK1249401A1 (zh) | 2018-11-02 |
| KR20130040787A (ko) | 2013-04-24 |
| RU2012140450A (ru) | 2014-03-27 |
| CA2789665C (en) | 2020-06-16 |
| EP2538978B1 (en) | 2016-09-07 |
| US20120316197A1 (en) | 2012-12-13 |
| BR112012020236A2 (pt) | 2016-05-17 |
| CA3009937A1 (en) | 2011-08-25 |
| CN102770159A (zh) | 2012-11-07 |
| MX2012009503A (es) | 2012-09-12 |
| CA2789665A1 (en) | 2011-08-25 |
| WO2011102149A1 (en) | 2011-08-25 |
| HK1178088A1 (zh) | 2013-09-06 |
| JP2017095511A (ja) | 2017-06-01 |
| EP2538978A1 (en) | 2013-01-02 |
| JP2013520397A (ja) | 2013-06-06 |
| KR101780666B1 (ko) | 2017-09-21 |
| RU2571816C2 (ru) | 2015-12-20 |
| ES2600355T3 (es) | 2017-02-08 |
| CN107693518A (zh) | 2018-02-16 |
| US9457084B2 (en) | 2016-10-04 |
| JP6152643B2 (ja) | 2017-06-28 |
| CA3009937C (en) | 2020-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX341482B (es) | Antagonistas del receptor ep4 y su uso en el tratamiento de enfermedades mediadas por la il-23. | |
| HK1220386A1 (zh) | Ep4受体拮抗剂在软骨疾病的治疗中的用途 | |
| EA201390977A1 (ru) | Комбинация агониста опиоидных рецепторов и антагониста опиоидных рецепторов для лечения болезни паркинсона | |
| UA104489C2 (uk) | Сполуки для лікування дисліпідемії та споріднених хвороб | |
| MX2011011028A (es) | Agonista del receptor beta de hormona tiroidea novedoso. | |
| EA201592256A1 (ru) | Производные имидазопирролидинона и их применение при лечении заболеваний | |
| MD20140059A2 (en) | Substituted 4-phenyl-pyridines for the treatment of NK-1 receptor related diseases | |
| MX2016003457A (es) | Compuestos aminopirimidina sustituidos y metodos de uso. | |
| IN2012DN06720A (cg-RX-API-DMAC7.html) | ||
| MY186126A (en) | Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor | |
| MY155649A (en) | Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease | |
| EA202091303A2 (ru) | Композиция ингибитора jak для местного применения | |
| WO2011107608A8 (en) | Heterocyclic amides as rock inhibitors | |
| MX2014002395A (es) | Inhibidores de rock suaves, novedosos. | |
| BR112012023178A2 (pt) | ramidinas substituídas como antagonistas de receptor prostaglandina 2 | |
| WO2012116176A3 (en) | Asymmetric ureas and medical uses thereof | |
| EA201491007A1 (ru) | Лекарственные составы | |
| PH12014501195A1 (en) | Novel 2h-indazoles as ep2, receptor antagonists | |
| EA201390653A1 (ru) | Aa антагонисты как усилители когнитивной и моторной функций | |
| MX343165B (es) | Agonistas del receptor 5-ht4 para el tratamiento de demencia. | |
| UA117154C2 (uk) | Антагоністи s1p3 | |
| MX2013006768A (es) | Moduladores de receptor de glucagon. | |
| IN2013DN02555A (cg-RX-API-DMAC7.html) | ||
| PH12014501943A1 (en) | Novel compounds for the treatment of dyslipidemia and related diseases | |
| MX2014014066A (es) | Compuestos de cromano. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |